-
1
-
-
0141781235
-
Fluoroquinolone AUIC break-points and the link to bacterial killing rates. Part 2: Human trials
-
DOI 10.1345/aph.1C419
-
Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break-points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003;37:1478-88. DOI 10.1345/aph.1C419
-
(2003)
Ann Pharmacother
, vol.37
, pp. 1478-1488
-
-
Schentag, J.J.1
Meagher, A.K.2
Forrest, A.3
-
2
-
-
0027258453
-
Population pharmacokinetic methods to optimise antibiotic effects
-
Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimise antibiotic effects. Drug Invest 1993;5:256-68.
-
(1993)
Drug Invest
, vol.5
, pp. 256-268
-
-
Amsden, G.W.1
Ballow, C.H.2
Schentag, J.J.3
-
3
-
-
0032515386
-
Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
-
Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
-
(1998)
JAMA
, vol.279
, pp. 125-129
-
-
Preston, S.L.1
Drusano, G.L.2
Berman, A.L.3
Fowler, C.L.4
Chow, A.T.5
Dornseif, B.6
-
4
-
-
0027161344
-
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
-
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
-
(1993)
Antimicrob Agents Chemother
, vol.37
, pp. 1073-1081
-
-
Forrest, A.1
Nix, D.E.2
Ballow, C.H.3
Goss, T.F.4
Birmingham, M.C.5
Schentag, J.J.6
-
5
-
-
0022000170
-
Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia
-
Schentag JJ, Vari AJ, Winslade NE, Swanson DJ, Smith IL, Simons GW, et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985;78:34-41.
-
(1985)
Am J Med
, vol.78
, pp. 34-41
-
-
Schentag, J.J.1
Vari, A.J.2
Winslade, N.E.3
Swanson, D.J.4
Smith, I.L.5
Simons, G.W.6
-
6
-
-
0034870049
-
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
-
Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231-44.
-
(2001)
Clin Ther
, vol.23
, pp. 1231-1244
-
-
Smith, P.F.1
Ballow, C.H.2
Booker, B.M.3
Forrest, A.4
Schentag, J.J.5
-
7
-
-
0033837432
-
Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells
-
Garcia I, Pascual A, Ballesta S, Perea EJ. Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. Int J Antimicrob Agents 2000;15:201-5.
-
(2000)
Int J Antimicrob Agents
, vol.15
, pp. 201-205
-
-
Garcia, I.1
Pascual, A.2
Ballesta, S.3
Perea, E.J.4
-
8
-
-
0036128763
-
Effects of gati-floxacin on phagocytosis, intracellular killing and oxidant radical production by human polymorphonuclear neutrophils
-
Braga PC, Dal Sasso M, Bovio C, Zavaroni E, Fonti E. Effects of gati-floxacin on phagocytosis, intracellular killing and oxidant radical production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 2002;19:183-7.
-
(2002)
Int J Antimicrob Agents
, vol.19
, pp. 183-187
-
-
Braga, P.C.1
Dal Sasso, M.2
Bovio, C.3
Zavaroni, E.4
Fonti, E.5
-
9
-
-
0037695856
-
Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae (SP)
-
San Diego, September 27-30
-
Kiem S, Craig WA. Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoroquinolones against Streptococcus pneumoniae (SP) (abstract A-492). In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
-
(2002)
Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Kiem, S.1
Craig, W.A.2
-
11
-
-
0035867022
-
What have we learned from pharmacokinetic and pharmacodynamic theories?
-
Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(supple 1):S39-46.
-
(2001)
Clin Infect Dis
, vol.32
, Issue.SUPPL. 1
-
-
Schentag, J.J.1
Gilliland, K.K.2
Paladino, J.A.3
-
12
-
-
0034812780
-
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
-
Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer H, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 2793-2797
-
-
Ambrose, P.G.1
Grasela, D.M.2
Grasela, T.H.3
Passarell, J.4
Mayer, H.5
Pierce, P.F.6
-
13
-
-
0031474148
-
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
-
Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(suppl A):45-57.
-
(1997)
J Antimicrob Chemother
, vol.40
, Issue.SUPPL. A
, pp. 45-57
-
-
Forrest, A.1
Chodosh, S.2
Amantea, M.A.3
Collins, D.A.4
Schentag, J.J.5
-
14
-
-
85037439615
-
Pharmacodynamics of levofloxacin with different organisms: One size does not fit all
-
Toronto, September 17-20
-
Jumbe NL, Louie A, Liu W, Deziel M, Miller MH, Drusano GL. Pharmacodynamics of levofloxacin with different organisms: one size does not fit all (abstract 291). In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000.
-
(2000)
Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Jumbe, N.L.1
Louie, A.2
Liu, W.3
Deziel, M.4
Miller, M.H.5
Drusano, G.L.6
-
16
-
-
0032515371
-
Antibiotic dosing - Does one size fit all?
-
Schentag JJ. Antibiotic dosing - does one size fit all? JAMA 1998; 279:159-60.
-
(1998)
JAMA
, vol.279
, pp. 159-160
-
-
Schentag, J.J.1
-
17
-
-
0034959819
-
Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention
-
American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
-
(2001)
Am J Respir Crit Care Med
, vol.163
, pp. 1730-1754
-
-
-
18
-
-
0031940776
-
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
-
Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 521-527
-
-
Thomas, J.K.1
Forrest, A.2
Bhavnani, S.M.3
Hyatt, J.M.4
Cheng, A.5
Ballow, C.H.6
-
19
-
-
0037100548
-
Why the AUC/MIC ratio should not be used to predict the effects of β-lactams
-
Mouton JW. Why the AUC/MIC ratio should not be used to predict the effects of β-lactams. Clin Infect Dis 2002;35:209-10.
-
(2002)
Clin Infect Dis
, vol.35
, pp. 209-210
-
-
Mouton, J.W.1
|